BIOMAT Database Logo BIOMAT Database Logo

Diurnal profile of pancreatic polypeptide, pancreatic glucagon, gut glucagon and insulin in human morbid obesity. 1983

J J Holst, and T W Schwartz, and N A Lovgreen, and O Pedersen, and H Beck-Nielsen

The diurnal profiles of pancreatic glucagon, insulin, pancreatic polypeptide (PP), and enteroglucagon were studied in five obese non-diabetic subjects (195 +/- 11 per cent of ideal body weight) and in six age matched controls. All the subjects were served with ordinary mixed meals five times during the day. The obese subjects were normoglycemic but hyperinsulinemic. Both groups showed rapid increases in PP to all meals, but the PP-response was significantly impaired in the obese group during the first part of the day. Normal subjects showed significant enteroglucagon responses to all meals, and had elevated levels throughout the day. In obese subjects, levels and responses were much lower at all times. Pancreatic glucagon profiles were similar. It is concluded that the possible role of abnormalities of PP and enteroglucagon secretion in the pathogenesis of human obesity deserves further study.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D008297 Male Males
D009765 Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
D010191 Pancreatic Polypeptide A 36-amino acid pancreatic hormone that is secreted mainly by endocrine cells found at the periphery of the ISLETS OF LANGERHANS and adjacent to cells containing SOMATOSTATIN and GLUCAGON. Pancreatic polypeptide (PP), when administered peripherally, can suppress gastric secretion, gastric emptying, pancreatic enzyme secretion, and appetite. A lack of pancreatic polypeptide (PP) has been associated with OBESITY in rats and mice. Pancreatic Polypeptide (PP),Pancreatic Polypeptide Hormone,Pancreatic Prohormone
D002940 Circadian Rhythm The regular recurrence, in cycles of about 24 hours, of biological processes or activities, such as sensitivity to drugs or environmental and physiological stimuli. Diurnal Rhythm,Nyctohemeral Rhythm,Twenty-Four Hour Rhythm,Nycthemeral Rhythm,Circadian Rhythms,Diurnal Rhythms,Nycthemeral Rhythms,Nyctohemeral Rhythms,Rhythm, Circadian,Rhythm, Diurnal,Rhythm, Nycthemeral,Rhythm, Nyctohemeral,Rhythm, Twenty-Four Hour,Rhythms, Circadian,Rhythms, Diurnal,Rhythms, Nycthemeral,Rhythms, Nyctohemeral,Rhythms, Twenty-Four Hour,Twenty Four Hour Rhythm,Twenty-Four Hour Rhythms
D004763 Glucagon-Like Peptides Peptides derived from proglucagon which is also the precursor of pancreatic GLUCAGON. Despite expression of proglucagon in multiple tissues, the major production site of glucagon-like peptides (GLPs) is the INTESTINAL L CELLS. GLPs include glucagon-like peptide 1, glucagon-like peptide 2, and the various truncated forms. Enteroglucagon,Enteroglucagons,Glucagon-Like Peptide,Glucagon-Like Polypeptide,Gut Glucagon,Glucagon-Like Polypeptides,Glucagon Like Peptide,Glucagon Like Peptides,Glucagon Like Polypeptide,Glucagon Like Polypeptides,Glucagon, Gut,Peptide, Glucagon-Like,Polypeptide, Glucagon-Like
D005260 Female Females
D005768 Gastrointestinal Hormones HORMONES secreted by the gastrointestinal mucosa that affect the timing or the quality of secretion of digestive enzymes, and regulate the motor activity of the digestive system organs. Enteric Hormone,Enteric Hormones,Gastrointestinal Hormone,Intestinal Hormone,Intestinal Hormones,Hormone, Enteric,Hormone, Gastrointestinal,Hormone, Intestinal,Hormones, Enteric,Hormones, Gastrointestinal,Hormones, Intestinal
D005934 Glucagon A 29-amino acid pancreatic peptide derived from proglucagon which is also the precursor of intestinal GLUCAGON-LIKE PEPTIDES. Glucagon is secreted by PANCREATIC ALPHA CELLS and plays an important role in regulation of BLOOD GLUCOSE concentration, ketone metabolism, and several other biochemical and physiological processes. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1511) Glucagon (1-29),Glukagon,HG-Factor,Hyperglycemic-Glycogenolytic Factor,Proglucagon (33-61),HG Factor,Hyperglycemic Glycogenolytic Factor
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

J J Holst, and T W Schwartz, and N A Lovgreen, and O Pedersen, and H Beck-Nielsen
Pancreatic polypeptide, pancreatic glucagon and enteroglucagon in morbid obesity and following gastric bypass operation.
January 1986, International journal of obesity,
J J Holst, and T W Schwartz, and N A Lovgreen, and O Pedersen, and H Beck-Nielsen
Diurnal profile of pancreatic exocrine secretion and plasma levels of gut hormones (cholecystokinin and pancreatic polypeptide).
December 1987, Gastroenterologia Japonica,
J J Holst, and T W Schwartz, and N A Lovgreen, and O Pedersen, and H Beck-Nielsen
Insulin, pancreatic polypeptide, and glucagon antibodies in insulin-dependent diabetes mellitus.
January 1981, Diabetes care,
J J Holst, and T W Schwartz, and N A Lovgreen, and O Pedersen, and H Beck-Nielsen
Opossum insulin, glucagon and pancreatic polypeptide: amino acid sequences.
January 1989, Peptides,
J J Holst, and T W Schwartz, and N A Lovgreen, and O Pedersen, and H Beck-Nielsen
Antibodies to insulin, pancreatic polypeptide, glucagon, and somatostatin in insulin-treated diabetics.
May 1981, The Journal of clinical endocrinology and metabolism,
J J Holst, and T W Schwartz, and N A Lovgreen, and O Pedersen, and H Beck-Nielsen
Time course of content of insulin, glucagon and pancreatic polypeptide in human pancreatic tissue obtained by surgery.
June 1981, Endocrinologia japonica,
J J Holst, and T W Schwartz, and N A Lovgreen, and O Pedersen, and H Beck-Nielsen
Effect of bombesin on plasma insulin, pancreatic glucagon, and gut glucagon in man.
April 1983, The Journal of clinical endocrinology and metabolism,
J J Holst, and T W Schwartz, and N A Lovgreen, and O Pedersen, and H Beck-Nielsen
Regional pancreatic concentration and in-vitro secretion of canine pancreatic polypeptide, insulin, and glucagon.
February 1978, Diabetes,
J J Holst, and T W Schwartz, and N A Lovgreen, and O Pedersen, and H Beck-Nielsen
Twenty-four-hour variations of plasma pancreatic polypeptide, insulin and glucagon in normal human subjects.
August 1980, Endocrinologia japonica,
J J Holst, and T W Schwartz, and N A Lovgreen, and O Pedersen, and H Beck-Nielsen
Somatostatin and pancreatic polypeptide secretion: effects of glucagon, insulin, and arginine.
January 1979, Diabetes,
Copied contents to your clipboard!